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Objectives: Evidence indicates a relationship between obesity and infection. We assessed the prevalence of
obesity in hospitalized patients and evaluated its impact on antimicrobial management.
Methods: Three National Health Service hospitals in London in 2011–12 were included in a cross-sectional study.
Data from all adult admissions units and medical and surgical wards were collected. Patient data were collected
from the medication charts and nursing and medical notes. Antimicrobial therapy was defined as ‘complicated’ if
the patient’s therapy met two or more of the following criteria: (i) second- or third-line therapy according to local
policy; (ii) intravenous therapy where an alternative oral therapy was appropriate; (iii) longer than the recom-
mended duration of therapy as per local policy recommendations; (iv) repeated courses of therapy to treat
the same infection; and (v) specialist advice on antimicrobial therapy provided by the medical microbiology or
infectious diseases teams.
Results: Of the 1014 patients included in this study, 22% (225) were obese, 69% (696) were normal/overweight
and 9% (93) were underweight. Obese patients were significantly more likely to have more complicated anti-
microbial therapy than normal/overweight and underweight patients (36% versus 19% and 23%, respectively,
P¼0.002). After adjustment for hospital, age group, comorbidities and the type of infection, obese patients
remained at significantly increased odds of receiving complicated antimicrobial therapy compared with
normal/overweight patients (OR¼2.01, 95% CI 1.75–3.45).
Conclusions: One in five hospitalized patients is obese. Compared with the underweight and normal/overweight,
the antimicrobial management in the obese is significantly more complicated.
Introduction
The global burden of obesity is reaching unprecedented levels. It is
estimated that if the current trend in obesity continues, 3 in 4 of
the US population and 7 in 10 of the UK population will be obese
by 2030.1 The health implications are immense. Obesity is asso-
ciated with significant health complications and morbidity, in-
cluding diabetes, cancer and heart disease.2 Emerging data
indicate a link between infection and obesity, with obese patients:
(i) being at higher risk of infection, in particular healthcare-
associated infection; and (ii) having poorer infection-related
clinical outcomes.3 Obesity is a recognized, independent risk
factor in surgical site infections following particular procedures
(e.g. vascular and cardiothoracic surgery), where obesity signifi-
cantly increases the risk of surgical site infections.4 Infections in
critical care,5 cardiology,6 gynaecology7 and orthopaedics8 have
also been reported as more prevalent among obese patients.
Obese patients have also been identified as being at higher risk
of respiratory tract infections9,10 and Clostridium difficile11 infec-
tions. These infections are a major health threat worldwide,
with significant socio-economic impact on the health infrastruc-
ture. Despite the growing evidence implicating obesity as a
major risk factor for healthcare-associated infections, little evi-
dence exists as to the possible reasons for this association
between obesity and infection.12
Obesity is most commonly defined using the standardized BMI
equation: weight (kg) divided by height (m) squared. According to
this WHO-ratified equation, a BMI of .30 kg/m2 is defined as
obese and a BMI of .40 kg/m2 is defined as morbidly obese.
Therefore, to understand the prevalence of obesity in populations,
accurate information on weight and height of individuals is
required. Despite not distinguishing between body fat and muscle,
BMI is currently the most widely accepted and used scale to
define obesity.
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Adipose tissue can act as an endocrine organ and exert immu-
nomodulatory effects on the body.13 Although the full effect of
this immunomodulation in obesity is unknown, it is plausible
that it may be a contributing factor to the observed outcomes
of infection among obese people. One other factor contributing
to the observed poorer infection outcomes among obese patients
may be inadequate antimicrobial dosing due to both: (i) lack
of weight-related dosing adjustment;14 and (ii) paucity of evi-
dence on dosing due to lack of antimicrobial pharmacokinetic
studies.3,15 The volume of distribution and renal clearance is
increased in obese individuals and there are also changes in
serum protein levels and hepatic metabolism.15 These physio-
logical changes in obesity can alter the bioavailability of drugs
and therefore have implications for drug dosing in obese indivi-
duals. In antimicrobial dosing, achieving the right concentrations
at the site of infection is paramount both to ensure efficacious
therapy and to prevent emergence of resistance by exposing
pathogens to sub-therapeutic concentrations of antimicrobials.
Despite this, there remains a significant gap in scientific literature
on appropriate dosing of antimicrobials among obese patients for
both treatment and surgical prophylaxis, with only limited and
mainly anecdotal evidence from pharmacokinetic studies.16
Whilst there are overall population data on obesity and limited
data on prevalence of obesity17 in hospitalized patients, there
are no data on the relationship between obesity and antimicrobial
therapy in practice. At the Imperial College Healthcare National
Health Service (NHS) Hospitals Organisation we serve a densely
populated urban community and have the largest bariatric centre
in Europe. We report here on a cross-sectional study investigating
the prevalence of obesity in hospitalized patients and the associa-
tions between obesity and antimicrobial therapy. Our aim was to
measure the prevalence of obesity in hospitalized adult patients
and evaluate the impact of obesity on infection and antimicrobial
management in this population.
Methods
Study design and population
This was a cross-sectional study that included data collected in three hos-
pitals of a multisite, 1500 bed NHS hospital organization in London. Data
were collected in two cross sections between March 2011–September
2011 and July 2012–August 2012. Existing local antibiotic consumption
data indicated that seasonal variability was not significant. Adult admis-
sions units and medical and surgical wards on all three hospital sites were
selected for the purpose of identifying the study population. The same
wards were included in both episodes of data collection. The data for
each patient were collected in a single day to provide a snapshot of patient
episodes. All patients physically present on the ward at the time of data
collection were eligible to be included in the study. Patients who were
away from the ward for a procedure or an operation were excluded from
the study, as were patients whose notes were unavailable at the time that
the study investigators were on the ward. This was because patients who
were physically absent from the ward could not be assessed for obesity,
and patients whose notes were missing could not have their medical
data included in the study.
Ethics approval
Ethics approval to conduct this study was obtained from the Joint
Research Compliance Office (JRCO) of Imperial College Healthcare
NHS Hospital and Imperial College London. Formal approval from the
National Research Ethics Service was not required for this research as
the JRCO identified the work as hospital service evaluation and audit.
Data collection
At the time of the study the hospitals did not have electronic medical
records or prescribing systems and all data sources were paper records
on the wards. A data collection form was designed and piloted prior to
the study and all data were gathered using this single form. Patient medi-
cation charts and nursing and medical notes were screened to collect the
data. Data were collected by author E. C. with assistance from specially
trained researchers. Data entered into the final database were double
checked for accuracy by one of the researchers.
To assess participants for obesity, recorded height and weight informa-
tion was collected where it was available. Not all hospital wards had work-
ing scales and it was not possible to measure each patient’s height and
weight. Therefore, in addition to collecting the recorded height and weight
from the medical records, a pre-validated figure rating scale (FRS) was
used.18 The FRS used was a gender-specific, pictorial, BMI-based body
size guide for men and for women. The scale had been validated in a
study with 400 participants.18 To measure obesity using the FRS, each
patient who was on the ward when the investigators were collecting
data was independently assessed by at least one of the investigators
and the result recorded. To assess inter-rater reliability of obesity using
the FRS, wherever it was possible two investigators independently
assessed the study participants using the scale.
Participant demographic data (e.g. age, gender and date of birth),
medication history, reason for admission and comorbidity data were col-
lected from the medical notes. Current medication, including antimicro-
bials (and the indication), for the admission episode was collected from
the medication charts. For every participant, all courses of antimicrobial
prescribing for an active infection were recorded. Antimicrobials adminis-
tered for HIV and TB were excluded as patients would have been on these
therapies for a long time. Antimicrobials prescribed for prophylaxis were
also excluded from this study.
Patients were considered to have received a ‘complex antimicrobial
therapy’ if they scored yes for two or more of the following criteria: (i)
second- or third-line therapy according to local policy (second- and third-
line therapy in the policy is reserved for more severe/complicated infec-
tions); (ii) intravenous therapy where an alternative oral therapy was
appropriate; (iii) longer than the recommended duration of therapy as
per local policy recommendations; (iv) repeated courses of therapy to
treat the same infection; and (v) specialist advice on antimicrobial therapy
provided by the medical microbiology or infectious diseases teams. The
dose and frequency of all antimicrobial courses were recorded to assess
whether any dosing adjustments were made based on weight for those
antimicrobials that required it or whether any patients had their dose
increased due to being overweight or obese.
Data analysis
Demographic information, comorbidity information and infection-related
outcomes of the study population were described and compared accord-
ing to the patient weight category, using the x2 test, Fisher’s exact test and
ANOVA tests where appropriate. To validate the accuracy of the FRS as a
measure of obesity, the k coefficient (a statistical measure of inter-rater
agreement for categorical variables) was calculated for participants who
had both a BMI (using recorded height and weight) and an FRS reading.
Values of k were interpreted using established thresholds.19
Univariate and stepwise multivariable logistic regression were used for
the analysis of the association between patient weight category (using
‘normal/overweight’ as the reference group) and the composite outcome
‘complex antimicrobial therapy’. Exploratory univariate investigation of
confounding and interaction were assessed for the following factors:
patient weight category, study site, age, gender, ethnicity, and reason
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Table 1. Univariate analysis of data by weight category
Normal/overweight
(n¼696)
Obese
(n¼225)
Underweight
(n¼93)
Total
(n¼1014)a Pb
Non-infection-related univariate analysis
Male (versus female), n (%) 386 (55.46) 101 (44.89) 33 (35.48) 520 (51.28) ,0.001
Age (years) (n¼1012), mean (SD) 65.57 (18.74) 65.25 (15.65) 70.97 (18.20) 65.99 (18.10) 0.0036
17–34 60 (8.63) 11 (4.91) 4 (4.30) 75 (7.41)
35–64 228 (32.81) 79 (35.27) 23 (24.73) 330 (32.61)
65–79 236 (33.96) 95 (42.41) 31 (33.33) 362 (35.77)
80–100 171 (24.60) 39 (17.41) 35 (37.63) 245 (24.21) ,0.001
Ethnicity (n¼1003), n (%)
white British 380 (55.15) 117 (52.70) 49 (53.26) 546 (54.44)
white other 73 (10.60) 29 (13.06) 12 (13.04) 114 (11.37)
black other/black Caribbean 58 (8.42) 21 (9.46) 4 (4.35) 83 (8.28)
black African 39 (5.66) 11 (4.95) 6 (6.52) 56 (5.58)
Indian/Pakistani/Bangladeshi 58 (8.42) 18 (8.11) 6 (6.52) 82 (8.18)
other Asian 31 (4.50) 9 (4.05) 8 (8.70) 48 (4.79)
other 50 (7.26) 17 (7.66) 7 (7.61) 74 (7.38) 0.824
Site, n (%)
hospital 1 250 (35.92) 65 (28.89) 27 (29.03) 342 (33.73)
hospital 2 211 (30.32) 86 (38.22) 24 (25.81) 321 (31.66)
hospital 3 235 (33.76) 74 (32.89) 42 (45.16) 351 (34.62) 0.027
Accident and emergency admission, n (%) 364 (52.30) 101 (44.89) 52 (55.91) 517 (50.99)
Infection, n (%) 184 (26.44) 59 (26.22) 28 (30.11) 271 (26.73)
Planned surgery, n (%) 117 (16.81) 50 (22.22) 7 (7.53) 174 (17.16)
Planned procedure, n (%) 26 (3.74) 11 (4.89) 3 (3.23) 40 (3.94)
Other, n (%) 5 (0.72) 4 (1.78) 3 (3.23) 12 (1.18) 0.062
Comorbidities, n (%)
diabetes 158 (22.70) 87 (38.67) 12 (12.90) 257 (25.35) ,0.001
hypertension 298 (42.82) 144 (64.00) 37 (39.78) 479 (47.24) ,0.001
Number of specific comorbidities, mean (SD) 3.52 (2.56) 4.40 (2.53) 4.19 (2.28) 3.78 (2.56) ,0.001
0 104 (14.94) 14 (6.22) 5 (5.38) 123 (12.13)
1–3 260 (37.36) 67 (29.78) 33 (35.48) 360 (35.50)
4–6 267 (38.36) 109 (48.44) 43 (46.24) 419 (41.32)
≥7 65 (9.34) 35 (15.56) 12 (12.90) 112 (11.05) ,0.001
Number of all active medications (n¼994), n (%)
0–4 155 (22.66) 29 (13.24) 11 (12.09) 195 (19.62)
5–7 183 (26.75) 48 (21.92) 23 (25.27) 254 (25.55)
8–10 170 (24.85) 60 (27.40) 28 (30.77) 258 (25.96)
≥11 176 (25.73) 82 (37.44) 29 (31.87) 287 (28.87) 0.002
Infection-related univariate analysis
Infection as reason for admission or acquired during stay, n (%) 331 (47.56) 115 (51.11) 46 (49.46) 492 (48.52) 0.639
Patients who had an infection as reason for admission or who acquired subsequent infection in hospital (n5492)
Infection by category, n (%)
infection other 175 (52.87) 45 (39.13) 18 (39.13) 238 (48.37)
hepatobiliary 23 (6.95) 9 (7.83) 0 32 (6.50)
pneumonia 62 (18.73) 21 (18.26) 15 (32.61) 98 (19.92)
surgical site infection 10 (3.02) 8 (6.96) 0 18 (3.66)
skin and soft tissue 25 (7.55) 21 (18.26) 3 (6.52) 49 (9.96)
urinary tract infection 36 (10.88) 11 (9.57) 10 (21.74) 57 (11.59) ,0.001
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for admission, presence or not of comorbidities, i.e. diabetes and hyperten-
sion, number of specific comorbidities, number of current medications
other than antibiotic and the type of infection. All variables with a
P value ,0.25 in an unadjusted univariate analysis were included in the
multivariate logistic regression. A backward elimination approach was
conducted to investigate the association between patient weight category
and complicated antimicrobial therapy on a patient, adjusted for the con-
founding factors. Models were compared using a likelihood ratio test. The
final model included covariates found to be significant in our regression
model (P,0.05) and was controlled for confounding factors identified in
the literature, e.g. age. All analyses were conducted in STATA version 12
(StataCorp, College Station, TX, USA).
Results
In each episode of data collection 34 wards were visited. These
wards represent half of the available 1500 bed capacity across
the hospitals included in this study. A total of 1338 (741 in 2011
and 597 in 2012) patients were admitted in a hospital bed on the
day of data collection from the wards included in the study. Of
these patients, 1056 (78%) were recruited as participants in the
study. Due to incomplete data collection, 42 participants were
excluded from the final analysis, so that the final number of par-
ticipants in the study was 1014 (76%).
Validation of the FRS
Height and weight were inconsistently recorded for the partici-
pants in their medical notes. This meant that BMI could only
be calculated for 491 (48%) of the participants. The FRS was
available for 100% of the participants. We found excellent agree-
ment between BMI and FRS (k¼0.823, SE¼0.036). As a result of
this, the FRS was used to categorize participants as obese or
non-obese.
Prevalence of obesity and its impact on antimicrobial
therapy
Of the patients assessed using the FRS (n¼1014), 22% (225) were
obese, 9% (93) were underweight and 69% (696) were in the
normal/overweight category. Women were significantly more
likely than men to be obese (55% versus 45%, P,0.001).
Elderly people (.80 years) were significantly more likely than
any other age group to be underweight than obese (38% versus
17%, P,0.001) (Table 1).
Compared with the others, obese patients were significantly
more likely to suffer from hypertension and diabetes. The num-
ber of comorbidities (e.g. hypertension, diabetes and cardiovas-
cular diseases) was significantly greater in obese patients, with
16% of obese patients having more than seven comorbidities
versus 9% in the normal/overweight category (P,0.001)
(Table 1).
Infection as a reason for admission was not significantly differ-
ent across the weight groups. Planned surgery was a more likely
reason for admission among obese patients. Skin and soft-tissue
infections were significantly more prevalent among obese
patients than the normal/overweight and underweight categories
(18% versus 8% and 7%, P,0.001). Surgical site infections were
also more prevalent in obese patients compared with normal/
overweight categories (7% versus 3%, P¼0.03). Obese patients
were significantly more likely to have more complicated anti-
microbial therapy than normal/overweight and underweight
patients (36% versus 19% and 23%, respectively, P¼0.002).
However, among the obese patients receiving systemic antimicro-
bials (421), we found no evidence of any dose adjustments made
based on patient weight. Before adjusting for other factors the
odds of obese patients having complicated antimicrobial therapy
was greater than for normal/overweight patients (OR¼2.48, 95%
CI 1.49 –4.11); there was no significant difference between
underweight and normal/overweight patients (OR¼1.28, 95%
CI 0.57–2.85). After adjusting for hospital, age group, comorbid-
ities (i.e. diabetes and hypertension) and the type of infection,
obese patients remained at significantly increased odds of com-
plicated antimicrobial therapy compared with normal/overweight
patients (OR¼2.01, 95% CI 1.72–3.45) (Table 2), although this did
not include any necessary dose adjustments for weight. No inter-
actions between patient weight and other confounders were
observed. No difference was observed in the odds of complicated
Table 1. Continued
Normal/overweight
(n¼696)
Obese
(n¼225)
Underweight
(n¼93)
Total
(n¼1014)a Pb
Patients receiving antimicrobials for active infection (n5421)
Complicated antimicrobial therapy 52 (18.51) 36 (36.00) 9 (22.50) 97 (23.04) 0.002
Number of antimicrobials/patient
1 160 (56.94) 56 (56.00) 28 (70.00) 244 (57.96)
2–5 121 (43.06) 44 (44.00) 12 (30.00) 177 (17.46) 0.265
Specialist input 29 (10.32) 17 (17.00) 1 (2.50) 47 (11.16) 0.036
Route of antimicrobials (n¼415)
oral 145 (52.35) 52 (52.00) 27 (71.05) 224 (53.98)
intravenous 128 (46.21) 48 (48.00) 11 (28.95) 187 (45.06)
nasogastric 4 (1.44) 0 0 4 (0.96) 0.152
aWhere n,1014, due to missing data, the number (n) of participants is given in brackets next to the category in the table.
bStatistical significances are by x2 test and Fisher’s exact test.
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Table 2. Multiple logistic regression examining the association between complicated antimicrobial therapy and weight after adjusting for potential
confounders (n¼421)
Predictor Unadjusted OR 95% CI Crude Pa Adjusted OR 95% CI Adjusted Pa
Weight
normal/overweight reference reference
obese 2.48 1.49–4.11 ,0.001 2.01 1.72–3.45 0.01
underweight 1.28 0.57–2.85 0.55 1.26 0.54–2.95 0.59
Age (years)
17–34 reference reference
35–64 2.90 0.96–8.71 0.06 2.07 0.66–6.47 0.21
65–79 2.76 0.92–8.30 0.07 1.93 0.62–6.06 0.26
80–100 1.58 0.48–5.22 0.46 1.25 0.36–4.37 0.73
Gender
male (versus female) 0.87 0.55–1.36 0.53
Ethnicity
white British reference
white other 1.64 0.80–3.38 0.18
black other/Black Caribbean 1.17 0.45–3.09 0.75
black African 1.24 4.67–3.27 0.67
Indian/Pakistani/Bangladeshi 1.96 0.95–4.01 0.07
other Asian 1.83 0.70–4.74 0.22
other 0.70 0.26–1.91 0.49
Site
hospital 1 reference reference
hospital 2 1.88 1.04–3.40 0.04 1.98 1.06–3.71 0.03
hospital 3 0.97 0.52–1.83 0.94 0.93 0.48–1.81 0.83
Reason for admission
Accident and emergency admission reference
infection 1.39 0.81–2.38 0.24
planned surgery 1.51 0.77–2.96 0.23
planned procedure 1.04 0.21–5.20 0.96
other 1
Diabetes
yes (versus no) 1.26 0.76–2.08 0.37
Hypertension
yes (versus no) 1.46 0.93–2.31 0.10
Number of specific comorbidities 1.02 0.94–1.11 0.59
0 reference
1–3 1.04 0.48–2.26 0.92
4–6 1.69 0.81–3.54 0.16
≥7 1.04 0.40–2.70 0.93
Number of current medications
0–4 reference
5–7 1.25 0.53–2.98 0.611
8–10 1.74 0.78–3.86 0.175
≥11 2.03 0.95–4.36 0.067
Type of infection
infection other reference reference
hepatobiliary 1.85 0.76–4.50 0.17 1.73 0.68–4.38 0.25
pneumonia 2.54 1.38–4.66 0.003 2.61 1.37–4.97 0.003
Continued
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antimicrobial therapy in underweight patients compared with
normal/overweight patients.
Discussion
In this study, we found that obese patients were more likely to
be receiving complicated antimicrobial therapy regimes in the
hospital setting. More complicated antimicrobial therapy in
the obese patient carries clinical and economic consequences,
particularly as obesity is increasing in both developed and
developing countries and antimicrobial resistance remains a
potent public health threat.1,11 There have been several papers
recently discussing the need to conduct further studies to
investigate the impact of obesity on dosing of different anti-
microbial agents.3,14,16 Obese patients remained at higher
odds of receiving complicated antibiotic therapy after adjust-
ment for confounding factors, such as age group, comorbidities
(i.e. diabetes and hypertension) and the type of infection. Obese
individuals were also more likely to be receiving intravenous anti-
biotics and be under specialist care and be receiving longer
courses of therapy.
We found that no dose adjustments were made in the prescrib-
ing of antimicrobials for obese patients. The lack of antimicrobial
dosing adjustments based on weight may mean that obese
individuals who acquire infections are at higher risk of receiving
sub-therapeutic antimicrobial levels.19 Sub-therapeutic dosing of
antimicrobials can select for resistance. The threat that sub-
therapeutic dosing of antimicrobials poses to emergence of
drug resistance should not be underestimated, in particular in
developing countries, where obesity is on the rise and access to
effective and safe antimicrobials remains a problem, making the
need to get therapy right the first time imperative.20
To make accurate recommendations about dosing adjust-
ments in obesity, pharmacokinetic and pharmacodynamic stud-
ies are required for a large proportion of commonly used
antibiotics, to measure the true association between body fat
and antimicrobial levels. Until such studies are conducted, anti-
microbial therapy in obesity will remain a grey area where clinical
acumen, supplemented by anecdotal experience and limited data
from small studies, will decide therapeutic outcomes.21 – 25 What
is imperative is that dosing decisions are made based on drug-
and patient-specific parameters. In the USA, attempts have
been made to integrate antimicrobial dosing adjustments for
obese patients. However, these initiatives have not been cohe-
sively adopted and the practice of adjusting doses in obese
patients remains erratic.20 In the absence of data from trials
and clear guidelines on dosing adjustments in obesity for indi-
vidual patients, there needs to be a more focused therapy for
obese hospitalized patients who acquire infections. In this
study, we did find antimicrobial therapies in the obese to be
more complicated.
The prevalence of obesity in the hospitalized patients in this
study reflects the increase in the prevalence of obesity in the UK,
with one in five patients in this study being classified as obese.
Half of the patients in this study were .65 years old, an age
group more associated with increased weight loss and malnutri-
tion;26 despite this, the prevalence of obesity remained high. In
addition to the observed association between obesity and diabetes
and hypertension, obese patients were also significantly more likely
to have other comorbidities. This increase in disease burden,
together with the associated medication burden, makes obese
people more likely to be frequent users of healthcare.
In this study, skin and soft-tissue infections were more likely
among obese patients, even when excluding surgical site infec-
tions. This association has been reported previously.27,28 We did
not find a significant difference in infection as an admission rea-
son across the different weight groups.
Limitations
The cross-sectional design is a limitation of this study. A longitu-
dinal study would have been more appropriate to detect causal
relationships between obesity and healthcare-acquired infections
and to compare the relative risks between the obese and the non-
obese. The data are a reflection of the diversity of the hospitalized
patient population in tertiary healthcare organizations. This study,
however, provides baseline data for further research into the
impact of obesity on antimicrobial dosing. In this study, we did
not use acuity of illness scores. Acuity of illness may have been
a confounder in this study.
Conclusions
In this study, one in five hospitalized patients was obese and obes-
ity was associated with more complicated antimicrobial therapy.
Even though the evidence base is inadequate for some antimicro-
bials, no dosing adjustments were found to be made in any of the
antimicrobial regimens of obese patients. Future studies need to
investigate the effect of obesity on antimicrobial outcomes.
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